Clinical Trials of Porcine anti-CDV Antibodies [IgG or F(ab’)2] in Canine Distemper Infected Dogs
Date Issued
2015
Date
2015
Author(s)
Chen, Ching-An
Abstract
Canine distemper (CD) is a globally distributed infectious disease caused by a morbillivirus of the family Paramyxoviridae. The canine distemper virus (CDV) causes one of the most contagious and lethal diseases of canids and wild carnivores. Porcine anti-CDV antibodies IgG and F(ab’)2 were both pilot products derived from Animal Department of Agriculture Technology Research Institute, Miaoli, Taiwan. A total of 29 CDV-naturally infected dogs with respiratory but not developing neurological signs were treated with a combination of IgG or F(ab’)2 and supportive therapy (group 1). Group 2 comprised 33 dogs with similar clinical signs that received only supportive therapy. The survival rate of group 1 (69%, 20/29) was significantly higher than that of group 2 (33.3%, 11/33) (p < 0.05). In group 1, five dogs (41.7%, 5/12) that developed neurological signs during therapy survived, compared to only one dog (4.8%, 1/21) in group 2, a significant difference (p < 0.05). In addition, no obvious severe side effects were observed during therapy. Only hyperthermia was observed in dogs that received IgG but not those that received F(ab’)2. In conclusion, porcine anti-CDV antibodies exhibit promising therapeutic efficacy with minimal side effect in the treatment of CD dogs. Besides dog, this therapy can be considered for treating other endangered animal species with CDV infection.
Subjects
canine distemper
passive immunotherapy
xenogeneic antibody
IgG
F(ab’)2
SDGs
Type
thesis
File(s)![Thumbnail Image]()
Loading...
Name
ntu-104-R01643008-1.pdf
Size
23.32 KB
Format
Adobe PDF
Checksum
(MD5):36e7a353955f35ce39afa175e293d335